92P ARCHER 1050: PHASE III RANDOMIZED STUDY OF 1ST-LINE DACOMITINIB (D) VS GEFITINIB (G) FOR ADVANCED (ADV) NON-SMALL CELL LUNG CANCER (NSCLC) IN PATIENTS (PTS) WITH ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION(S)

Autor: Mok, T.S.K., Nakagawa, K., Rosell, R., Wu, Y., Trygstad, C., Capizzi, R., DeBenedetto, R., Goldberg, Z., Wang, T., Antic, V.
Zdroj: In Lung Cancer May 2013 80 Supplement 1:S39-S40
Databáze: ScienceDirect
Externí odkaz: